Economic Costs of Shiga Toxin–Producing Escherichia coli Infection in Australia
To cite this article: Michelle McPherson, Martyn D. Kirk, Jane Raupach, Barry Combs, and Jim R.G. Butler. Foodborne Pathogens and Disease.
January 2011,
8(1): 55-62.
doi:10.1089/fpd.2010.0608.
Published in Volume: 8 Issue 1: January 8, 2011 Online Ahead of Print: November 17, 2010
Shiga toxin–producing Escherichia coli (STEC) infections are an important cause of foodborne disease in Australia. Three percent to 7% of sporadic patients develop hemolytic uremic syndrome (HUS) and 40% of patients with HUS develop chronic complications. To examine costs associated with illness, we interviewed patients notified to the South Australian Department of Health with a structured questionnaire regarding severity of illness, medical treatment, time lost from work, hospitalization, and other costs. In 2003–2006, we interviewed 46 patients of STEC infection, 2 of whom developed HUS. The median duration of illness was 7 days (range 3–31 days) and 41% (19/46) of patients were admitted to hospital. The estimated total cost for the 46 STEC cases in South Australia was AUD$144,087, equating to a mean cost of AUD$3132 per case. We estimate that the annual total costs of STEC infection in South Australia and Australia are AUD$200,283 and AUD$2,633,181, respectively. We used linear regression to identify that STEC infection costs increase by AUD$608 per day regardless of severity, and that more severe illness is strong predictor of cost. This is the first Australian study to examine costs of STEC infection and highlights the significant impact of this illness.
Users who read this article also read
Mar Masiá, Sergio Padilla, Catalina Robledano, Natividad López, José Manuel Ramos, Felix Gutiérrez
AIDS Research and Human Retroviruses.
March 2012: 242-246.
Desmond Barry Keenan, John Joseph Mastrototaro, Howard Zisser, Kenneth A. Cooper, Gautham Raghavendhar, Scott W. Lee, Jonathan Yusi, Timothy S. Bailey, Ronald Leonard Brazg, Rajiv V. Shah
Diabetes Technology & Therapeutics.
March 2012: 225-231.